C6orf57 Inhibitors
Chemical inhibitors of C6orf57 encompass a range of compounds that intervene in various signaling pathways, ultimately leading to the functional inhibition of this protein's activity within cells. Wortmannin and LY294002, for instance, are potent inhibitors of phosphoinositide 3-kinases (PI3K), disrupting the PI3K/AKT pathway, which is instrumental in the regulation of numerous cellular processes. The inhibition of this pathway by these chemicals results in the reduction of AKT phosphorylation and activity, leading to the inhibition of C6orf57, which is posited to be active in these cellular processes. Rapamycin, targeting the mammalian target of rapamycin (mTOR), a pivotal component in the same pathway, also ensures the downregulation of C6orf57 activity due to mTOR's integral role in cell growth and proliferation. Similarly, PD98059 and U0126, by inhibiting MEK, impede the MAPK/ERK pathway activation, where ERK's role in cellular proliferation and differentiation is well-established, thus affecting C6orf57 activity that may be regulated through this signaling cascade.
SB203580 and SP600125 specifically target the stress-activated MAP kinase pathways, with SB203580 inhibiting p38 MAP kinase, and SP600125 inhibiting c-Jun N-terminal kinase (JNK). The suppression of these kinases can lead to decreased cellular responsiveness to stress or cytokines, which is an aspect of cellular function that C6orf57 is believed to be associated with. Y-27632's inhibition of Rho-associated protein kinase (ROCK) can alter the regulation of the actin cytoskeleton, cell adhesion, and motility, processes which may implicate C6orf57 activity. In the realm of tyrosine kinase inhibition, PD173074 targets fibroblast growth factor receptors (FGFRs), thus potentially inhibiting C6orf57 activity if it is involved in FGFR-mediated signaling pathways. ALLN, on the other hand, prevents the degradation of proteins by inhibiting calpain and the proteasome, which may result in the stabilization of proteins that negatively regulate pathways involving C6orf57. Lastly, Bisindolylmaleimide I (GF 109203X) inhibits protein kinase C (PKC), and ZM 447439 targets Aurora kinases, both of which are pivotal in the regulation of cell cycle and mitosis, potentially leading to the functional inhibition of C6orf57 if its activity is linked to these processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of phosphoinositide 3-kinases (PI3K), and since PI3Ks are upstream regulators of the AKT signaling pathway, which controls a variety of cellular processes including metabolism, proliferation, cell survival, growth and angiogenesis, the inhibition of PI3K by Wortmannin could lead to a decrease in AKT phosphorylation and activity. Given that C6orf57 is involved in cellular processes that are affected by AKT signaling, its activity would be inhibited as a result of the PI3K pathway suppression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a central molecule in the PI3K/AKT/mTOR pathway, which is crucial for cell growth and proliferation. By inhibiting mTOR, Rapamycin could decrease the activity of downstream proteins that depend on this pathway, thereby functionally inhibiting the activity of C6orf57, which is involved in cellular growth processes regulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another specific inhibitor of PI3K, which would similarly inhibit the PI3K/AKT pathway, leading to reduced phosphorylation and activation of AKT. This decrease in AKT activity would inhibit the cellular processes that C6orf57 is involved in, thus functionally inhibiting C6orf57. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK, a kinase that can regulate various cellular functions including proliferation and differentiation. Inhibition of the MAPK/ERK pathway could therefore inhibit the function of C6orf57 that is mediated through this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in the response to stress and inflammation. By inhibiting p38 MAP kinase, SB203580 could inhibit the function of C6orf57 that is involved in cellular responses to stress signals regulated by this kinase. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also an inhibitor of MEK, preventing the activation of ERK1/2 in the MAPK/ERK pathway. Inhibition of this pathway could lead to a functional inhibition of C6orf57 if the protein's activity is regulated by ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), and the inhibition of JNK activity could lead to a decrease in the cellular responses to stress or cytokines that C6orf57 may be involved in, thereby functionally inhibiting the activity of C6orf57. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). ROCK is involved in regulating actin cytoskeleton, cell adhesion, and motility. By inhibiting ROCK, Y-27632 could functionally inhibit processes influenced by the actin cytoskeleton that C6orf57 may be involved in. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a selective inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinase. As FGFR signaling can regulate cellular differentiation and proliferation, inhibition of FGFR by PD173074 could result in functional inhibition of C6orf57 if it is involved in pathways regulated by FGFR. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I, also known as GF 109203X, is a specific inhibitor of protein kinase C (PKC). By inhibiting PKC, it could functionally inhibit signaling pathways that regulate various cellular processes, including those in which C6orf57 is involved, leading to its functional inhibition. | ||||||